Keros Therapeutics, Inc. (KROS) NASDAQ
10.72
-0.183(-1.68%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
10.72
-0.183(-1.68%)
Currency In USD
| Previous Close | 10.9 |
| Open | 10.96 |
| Day High | 11.09 |
| Day Low | 10.69 |
| 52-Week High | 22.55 |
| 52-Week Low | 9.79 |
| Volume | 210,284.46 |
| Average Volume | 421,873 |
| Market Cap | 342.92M |
| PE | -4.24 |
| EPS | -2.53 |
| Moving Average 50 Days | 11.38 |
| Moving Average 200 Days | 15.27 |
| Change | -0.18 |
Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS
GlobeNewswire Inc.
Mar 09, 2026 12:00 PM GMT
LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range o
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
GlobeNewswire Inc.
Mar 09, 2026 12:00 PM GMT
LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range o
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
GlobeNewswire Inc.
Mar 04, 2026 9:01 PM GMT
LEXINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range o